Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II radiotherapy plus durvalumab without prophylactic neck irradiation in head and neck squamous cell carcinoma (N0)
2018-001976-39Phase 2Active
- Sponsor
- GORTEC
- Start
- Oct 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in head and neck squamous cell carcinoma (HNSCC), Oral Mucosal Carcinoma, oropharyngeal squamous cell carcinoma (OPSCC) and 2 more, sponsored by GORTEC. Primary endpoint: Regional (neck) nodal control rate. Started Oct 2018; status: active.
02
Drugs
durvalumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)Oral Mucosal Carcinomaoropharyngeal squamous cell carcinoma (OPSCC)squamous cell carcinoma of the hypopharynxlaryngeal squamous cell carcinoma (LSCC)
Beyond the preview
Go deeper on 2018-001976-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001976-39.